GL1X · GenesisL1 explorer

Research workbench

Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1

Analyse Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
4C4H
Type
protein
Length
248 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Dual specificity protein kinase ttk
EC
2.7.12.1
UniProt
P33981
Ligands
7RO
Pockets
1 · best druggability 0.64

Structure

x-ray diffraction · 1 distinct chain · 38% helix, 21% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ADual specificity protein kinase ttk (EC 2.7.12.1)protein24838% helix, 21% strandP33981

Ligands and binding sites

  • 7RO · tert-butyl 6-((2-chloro-4-(dimethylcarbamoyl)phenyl)amino)-2-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate · ligand · chains A
  • 7PE · 2-(2-(2-(2-(2-(2-ethoxyethoxy)ethoxy)ethoxy)ethoxy) ethoxy)ethanol · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

1 pocket found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
12910.640.80327RO, 7PE

Compared structures

  • 4C4H · Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.